日久光電(003015.SZ):子公司擬投資建設年產600萬平方米功能性膜項目
格隆匯6月26日丨日久光電(003015.SZ)公佈,根據戰略發展規劃及經營發展需要,爲解決調光導電膜、光學膜及配套塗膠產品的產能需求,全資子公司浙江日久擬以自有資金或自籌資金約82,200萬元(最終以實際發生金額爲準)投資建設年產600萬平方米功能性膜項目。投資資金主要包含了土地購置、廠房及生產車間建設、生產設備投入、鋪底流動資金等。本項目的實施有助於提升公司功能性薄膜的生產能力,滿足調光導電膜、光學膜市場持續增長的需求,避免因產能不足造成業務訂單流失的風險,符合公司整體業務佈局和長期發展戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.